The perimenopause heart connection is finally getting attention in cardiology. Cardiovascular disease is the leading cause of death in women in the United States, a fact laid out in the American Heart Association’s scientific statement Menopause Transition and Cardiovascular Disease Risk (El Khoudary et al., Circulation 2020). That statement, drawing on decades of longitudinal cohort data, established the menopause transition itself, distinct from chronological aging, as a period of accelerated cardiovascular risk that shifts lipid profiles, body fat distribution, blood pressure, and vascular function within a few years.
The menopause transition changes cardiovascular biology, not just symptoms
Perimenopause, the window running from the first noticeable menstrual cycle changes to twelve consecutive months without a period, typically spans several years in the mid-40s to early 50s. During this window, ovarian estrogen production becomes erratic before falling durably. That endocrine shift drives measurable cardiovascular changes: low-density lipoprotein (LDL) cholesterol tends to rise, high-density lipoprotein (HDL) cholesterol quality falls even when its concentration does not, blood pressure rises, and body fat redistributes from the hips and thighs toward the abdomen. Visceral abdominal fat carries greater metabolic risk than subcutaneous fat, and its accumulation during the transition is one of the more consistent findings across cohort studies.
The 2020 AHA statement made this a formal clinical concern
Before 2020, the menopause transition was often folded into general aging in cardiovascular guidelines. The AHA scientific statement changed that framing. Its authors reviewed longitudinal data from cohorts including the Study of Women’s Health Across the Nation (SWAN) and concluded that adverse cardiometabolic changes accompanying midlife and the menopause transition require earlier attention. The statement placed the transition itself, independent of age, as a period of accelerated risk and called for earlier screening and intervention. In her comment to Healio when the statement was released, El Khoudary said the findings “underline the significance of the menopause transition as a time of accelerating CVD risk, thereby emphasizing the importance of monitoring women’s health during midlife.”
Sex-specific risk factors add to the general ones
Women carry cardiovascular risk factors that do not apply to men and that are often collected but rarely used in risk calculation. A history of preeclampsia, gestational diabetes, or preterm birth roughly doubles later cardiovascular risk. Polycystic ovary syndrome (PCOS), premature ovarian insufficiency (menopause before age 40), and migraine with aura each add measurable risk. These sit alongside the general risk factors of hypertension, dyslipidemia, smoking, and diabetes, and they should shift the clinical threshold for lipid testing and blood pressure follow-through during perimenopause.
The timing hypothesis reframes hormone therapy
The cardiovascular reputation of hormone therapy was set by the Women’s Health Initiative (WHI) trials in the early 2000s, which enrolled women whose average age was 63, more than a decade past menopause. Those studies found increased cardiovascular risk. The Early versus Late Intervention Trial with Estradiol (ELITE), published by Hodis and colleagues in the New England Journal of Medicine in 2016, tested the timing question directly: women randomized to estradiol within six years of menopause showed slowed progression of subclinical atherosclerosis, while those starting more than ten years out did not. A 2025 secondary analysis of the WHI trials, published in JAMA Internal Medicine, found that among women with vasomotor symptoms who initiated hormone therapy near menopause, cardiovascular event rates were not increased relative to placebo.
None of this makes hormone therapy a preventive cardiovascular drug. It shifts the calculus for a symptomatic perimenopausal woman with low background risk, who is not the woman WHI studied.
Treat perimenopause as a cardiovascular checkpoint
The practical implication of the AHA statement is that perimenopause is the time to screen blood pressure, get a lipid panel, ask about pregnancy history, and address weight, activity, sleep, and smoking early rather than after the metabolic window has closed. The relevant thresholds are the same used in any adult primary prevention assessment; the difference is timing. Body-mass index and waist measurements are simple starting points, though they miss the visceral shift; our BMI calculator provides a starting reference.
What the evidence cannot yet answer
The AHA statement calls out several gaps directly. Randomized trials in perimenopausal women, as opposed to postmenopausal, remain few. The optimal formulation and route of hormone therapy for cardiovascular safety in symptomatic women is not settled; transdermal estrogen appears to carry lower thromboembolic risk than oral, but head-to-head cardiovascular outcome data are limited. And the interaction between menopause-transition changes and cardiovascular risk in Black women, who have both higher baseline hypertension prevalence and earlier menopause, is under-studied and needs dedicated cohorts.
References
- El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation, 2020; 142: e506-e532. DOI: 10.1161/CIR.0000000000000912
- Hodis HN, Mack WJ, Henderson VW, et al. Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 2016; 374: 1221-1231. DOI: 10.1056/NEJMoa1505241
- Rossouw JE, Aragaki AK, Manson JE, et al. Menopausal Hormone Therapy and Cardiovascular Diseases in Women With Vasomotor Symptoms: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials. JAMA Internal Medicine, 2025; 185: 1330-1339. DOI: 10.1001/jamainternmed.2025.4510
- American College of Cardiology. Menopause Transition and CVD Risk: AHA Scientific Statement key points. Available at: acc.org